Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Serentis Inc.

Latest From Serentis Inc.

Avantium Pharma buyout creates new CRO Crystallics

Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.


New CEO at Phytopharm

Phytopharm (UK) has appointed Tim Sharpington chief executive officer and board director. Sandy Morrison, the company's interim CEO, will revert to his position as a non-executive director. Mr Sharpington has nearly 20 years' experience in the life sciences sector with various biotechnology and pharmaceutical service companies. In 2002, he was development director at Arakis, which was sold to Sosei in 2005 for £107 million. After leaving Arakis, he founded and became CEO of Serentis in 2006. Mr Sharpington is also a non-executive director of Clinical Force, a clinical trial software and service company.


Dr Robert Tansley joins Serentis

Dr Robert Tansley has joined the UK biopharmaceutical company Serentis as chief medical officer. He was previously development and medical director of Sosei R&D. Dr Tansley has also held roles in development and regulatory affairs at Sanofi, Roche, Arakis and as a medical assessor in the licensing division of the Medicines and Healthcare products Regulatory Agency (MHRA).


Heptares fundraising could provide hope for UK biotech

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Serentis Inc.
  • Senior Management
  • Tim Sharpington, CEO
    Peter Keen, Dir., Corp. Dev. & Fin.
    Alan Rothaul, PhD, CSO
    Robert Tansley, MD, CMO
  • Contact Info
  • Serentis Inc.
    Phone: (44) 1223 437064
    23 Cambridge Science Park
    Milton Rd.
    Cambridge, CB4 0EY